Wegovy? (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US

Media: | ||
Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Ann S?nderm?lle Rendb?k | +45 3075 2253 | arnd@novonordisk.com |
David Heiberg Landsted | +45 3077?6915 | dhel@novonordisk.com |
Mark Joseph Root?(US) | +1 848 213 3219 | mjhr@novonordisk.com |